)
Edge28 Aug 2026
Bigger, Sharper, IMAX: A Blockbuster Business
How IMAX turned an unscalable, large-screen format into the center of blockbuster filmmaking through cameras, projection, and remastering technology.
Spero Therapeutics
Spero Therapeutics (SPRO) investor relations material
Spero Therapeutics Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary28 Aug, 2026
Company overview and business model
Clinical-stage biopharmaceutical company focused on next-generation medicines for immune-mediated diseases.
Lead program, SP001, is a fully humanized monoclonal antibody targeting CD40 Ligand, licensed from Innovent Biologics and Fortvita Biologics for global development (excluding certain Asian territories).
Developing SP001 for Immunoglobulin G4 related disease, with potential for broader immune-mediated indications.
Financial performance and metrics
As of June 30, 2026, 58,146,910 shares of common stock outstanding; pro forma up to 140,791,538 shares if full offering is completed at $1.21/share.
Historical net tangible book value as of June 30, 2026: $44.2 million ($0.76/share); pro forma net tangible book value after offering: $141.1 million ($1.00/share).
Immediate dilution to new investors estimated at $0.21/share if offering is completed at $1.21/share.
Use of proceeds and capital allocation
Net proceeds intended for general corporate purposes, including clinical trials, R&D, working capital, capital expenditures, investments, acquisitions, and collaborations.
Management retains broad discretion over allocation of proceeds.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Spero Therapeutics
- FDA approval, $105M financing, and SP001 focus extend cash runway into 2029.SPRO
Q2 2026 - SP001 advances as a differentiated, potent therapy for IgG4-RD and Sjögren's disease.SPROCompany presentation
- All AGM proposals, including director elections and share increase, were approved by shareholders.SPROAGM 2026
- Net loss narrowed, cash runway extends to 2028, and tebipenem HBr awaits FDA decision.SPROQ1 2026
- Stockholders will vote on director elections, auditor ratification, compensation, share increase, and new incentives.SPROProxy filing
- Key votes include director elections, auditor ratification, and doubling authorized shares.SPROProxy filing
- Stockholders will vote on director elections, auditor ratification, compensation, share increase, and new incentives.SPROProxy filing
- Returned to profitability in 2025, driven by collaboration revenue and milestone payments.SPROQ4 2025
- Q2 net loss widened to $17.9M as R&D spending rose; cash runway extends into late 2025.SPROQ2 2024
Next Spero Therapeutics earnings date
H.C. Wainwright 28th Annual Global Investment Conference15 Sep, 2026
Spero Therapeutics
Next Spero Therapeutics earnings date
H.C. Wainwright 28th Annual Global Investment Conference15 Sep, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage